PDS Biotechnology (NASDAQ:PDSB) Stock Rating Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of PDS Biotechnology (NASDAQ:PDSB) from a hold rating to a sell rating in a research note released on Sunday morning,Wall Street Zen reports.

A number of other equities research analysts have also issued reports on PDSB. Weiss Ratings lowered PDS Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 11th. HC Wainwright reiterated a “buy” rating on shares of PDS Biotechnology in a research note on Wednesday, August 26th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $9.00.

PDS Biotechnology Price Performance

PDSB stock opened at $0.80 on Friday. The company’s 50-day moving average price is $0.50 and its 200 day moving average price is $0.79. PDS Biotechnology has a 52 week low of $0.20 and a 52 week high of $1.55. The company has a current ratio of 0.57, a quick ratio of 0.57 and a debt-to-equity ratio of 2.73. The company has a market cap of $44.61 million, a P/E ratio of -1.25 and a beta of 1.46.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). On average, research analysts expect that PDS Biotechnology will post -0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in PDS Biotechnology in the 2nd quarter worth $535,000. Renaissance Technologies LLC lifted its holdings in PDS Biotechnology by 25.0% during the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock worth $134,000 after buying an additional 44,100 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in PDS Biotechnology in the second quarter worth $60,000. 26.84% of the stock is owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company developing immunotherapies designed to stimulate the immune system to recognize and attack cancer cells. The company’s research is centered on its Versamune platform, which is intended to activate and enhance T-cell responses against specific disease-associated targets.

PDS Biotechnology’s lead programs include PDS0101, an investigational therapeutic candidate designed to generate immune responses against human papillomavirus type 16 (HPV16) antigens.